Influence of flow rate and uasage in drastic condition on the aerodynamic performance of a formoterol dry powder formulation using different kinds of capsules for inhalation

info:eu-repo/semantics/nonPublishe

Impact of capsule type on aerodynamic performance of inhalation products: A case study using a formoterol-lactose binary or ternary blend

The aerodynamic performance of a dry powder for inhalation depends on the formulation and the dry powder inhaler (DPI). In the case of capsule-based DPIs, the capsule also plays a role in the powder aerosolisation and the dispersion of the micronized drug during the inhalation. This study evaluated the impact of gelatine capsules (Quali-G™ and Hard Gelatine Capsules for DPIs), cold-gelled hypromellose (HPMC) capsules (Quali-V®-I and Vcaps®) and thermal-gelled HPMC capsules (Vcaps®Plus) from Qualicaps® and Capsugel® respectively, on the delivered dose (DD), fine particle dose (FPD), and capsule retention for formoterol-lactose binary and ternary blends. This study used a low resistance Axahaler® DPI based on the RS01 design (Plastiape, Italy). Similar trends were observed with the different capsule types that packaged both dry powder formulations. The highest DD and FPD and the lowest formoterol capsule retention were observed with cold-gelled HPMC capsules such as Quali-V-I® and Vcaps®, without significant differences between these capsules (p > 0.05, one-way ANOVA with Newman-Keuls post-hoc test) for both dry powders. Therefore, the capsule composition and manufacturing process have an influence on aerodynamic performance. In addition, the ternary blend showed higher DDs and FPDs but also higher capsule retention in comparison to the binary blend.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Impact of the capsule type on the aerodynamic performances of a fluticasone-based dry powder under optimal and suboptimal inhalation airflows

info:eu-repo/semantics/nonPublishe

Influence of Different Capsules for Inhalation on the Aerodynamic Performance of Formoterol Dry Powder Formulation at Different Flow Rates

info:eu-repo/semantics/publishe

A Comparative Evaluation of the Aerosolization Performances of Marketed Fluticasone Multi-Unit and Single-Unit Dry Powder Inhalers (DPIs): The Effects of Product Use Life, Suboptimal Airflow and a Hot/Humid Environment.

info:eu-repo/semantics/nonPublishe

Impact of different capsules for dry powder inhalers on the aerodynamic performances of formoterol-based binary and ternary blends

info:eu-repo/semantics/nonPublishe

A comparative evaluation of formoterol-based marketed inhaled medicines throughout the device life, focusing on inspiratory airflow and high temperature and humidity use conditions

info:eu-repo/semantics/nonPublishe

Evaluation of the aerodynamic performance of formoterol dry powder using different capsules for inhalation: hypromellose versus gelatin from Qualicaps and Capsugel

info:eu-repo/semantics/publishe

Proposed algorithm for healthcare professionals based on product characteristics and in vitro performances in different use conditions using formoterol-based marketed products for inhalation.

Healthcare professionals require an easy algorithm for selecting the most appropriate inhalation product for each patient at the beginning of a treatment. As a case study, we selected five marketed formoterol products: Foradil® and Formagal®, capsule-based dry powder inhalers (DPIs), Novolizer® Formoterol and Oxis®, reservoir-based DPIs and Formoair®, a pressurized metered dose inhaler. We generated an algorithm based on device properties (i.e. device handling, feedback and remaining dose/end of product indication) and in vitro aerodynamic performances (i) along the product use life in optimal conditions, (ii) at different airflows and (iii) after exposing pre-loaded doses to 40 °C and 75% relative humidity for 4 h. Based on these results, an algorithm was built where Formoair and Formagal can be proposed when there is high risk of humidity and for patients presenting suboptimal or optimal airflows. When no risk of humidity is present, Formoair, Foradil, Formagal and Novolizer Formoterol equipped with a trigger valve could be proposed for patients presenting suboptimal airflows. When no risk of humidity is present and for patients presenting optimal airflow, all products, including Oxis, could be proposed. Ultimately, the optimal inhalation product will be selected after checking the patient's preference and capacity for correct device handling and inhalation technique.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Marketed Formoterol Inhalation Aerosols: A comparative Evaluation to Determine the Place of Capsule-based Dry Powder Inhalers (DPIs)

info:eu-repo/semantics/publishe